Raghuram Selvaraj

Rodman & Renshaw’s Raghuram Selvaraj maintained a Buy rating for Valeant Pharmaceuticals Intl Inc (NYSE: VRX), with a price target of $118. Debt default is the most substantial risk that the company is facing. Analyst Raghuram Selvaraj pointed out, “It is important to note that...